Literature DB >> 28057391

Regional lymph node involvement in patients undergoing liver resection for colorectal cancer metastases.

S Nanji1, M E Tsang2, X Wei3, C M Booth4.   

Abstract

BACKGROUND: While the indications for surgery among patients with colorectal cancer liver metastases (CRCLM) are expanding, the role of surgery in patients with hepatic lymph node involvement remains controversial. We report management and outcomes in a population-based cohort of patients undergoing hepatectomy with concomitant hepatic lymphadenectomy for CRCLM.
METHODS: All cases of hepatectomy for CRCLM in the Canadian Province of Ontario from 2002 to 2009 were identified using the population-based Ontario Cancer Registry and linked electronic records of treatment. Pathology reports were used to identify concomitant lymphadenectomy with liver resection as well as extent of disease and surgical procedure.
RESULTS: Among 1310 patients who underwent resection for CRCLM, 103 (8%) underwent simultaneous regional lymphadenectomy. Seventy-one percent of cases with lymphadenectomy (70/103) had a major liver resection (≥3 segments). Of the 103 lymphadenectomy cases, 80 (78%) were hepatic pedicle, 16 (16%) were celiac and 7 (7%) were para-aortic. The mean number of nodes removed was 2.2 (range 1-15). Ninety-day mortality was 6%. Twenty-nine percent (30/103) of cases had positive nodes. Unadjusted overall survival at 5 years for positive vs negative nodes was 21% vs 42% (p = 0.003); cancer-specific survival was 10% vs 43% (p < 0.001). In adjusted analyses, hepatic node involvement was associated with inferior OS (HR 2.19, p = 0.010) and CSS (HR 3.07, p = 0.002).
CONCLUSIONS: Patients with resected CRC liver metastases with regional lymph node involvement have inferior survival compared to patients with negative nodes. Despite this poor prognostic factor, a small proportion of cases with involved nodes will achieve long-term survival.
Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Colorectal cancer liver metastases; Liver resection; Lymphadenectomy; Population-based study

Mesh:

Year:  2016        PMID: 28057391     DOI: 10.1016/j.ejso.2016.10.033

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

Review 1.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

2.  Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases.

Authors:  M Okuno; C Goumard; T Mizuno; S Kopetz; K Omichi; C-W D Tzeng; Y S Chun; J E Lee; J-N Vauthey; C Conrad
Journal:  Br J Surg       Date:  2018-04-17       Impact factor: 6.939

3.  Development and Validation of a Predictive Scoring System for Colorectal Cancer Patients With Liver Metastasis: A Population-Based Study.

Authors:  Yinghao Cao; Songqing Ke; Shenghe Deng; Lizhao Yan; Junnan Gu; Fuwei Mao; Yifan Xue; Changmin Zheng; Wentai Cai; Hongli Liu; Han Li; Fumei Shang; Zhuolun Sun; Ke Wu; Ning Zhao; Kailin Cai
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

4.  Prognostic Factors in Stage IV Colorectal Cancer Patients With Resection of Liver and/or Pulmonary Metastases: A Population-Based Cohort Study.

Authors:  Panxin Peng; Yusong Luan; Peng Sun; Liming Wang; Xufeng Zeng; Yangyang Wang; Xuhao Cai; Peide Ren; Yonggang Yu; Qi Liu; Haoyue Ma; Huijing Chang; Bolun Song; Xiaohua Fan; Yinggang Chen
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.